Deal of the Month: Pfizer

In the week ending March 20, the US pharmaceutical company Pfizer raised $13.5bn in the US dollar bond market in four tranches to repay the bulk of its $22.5bn bridge loan acquired in the purchase of fellow pharma firm Wyeth.

Even in the context of the most prolific quarter in the debt markets since records began, this constituted a very large transaction indeed. But what made it even more noteworthy was that it occurred only a month after Roche, another pharmaceutical, had taken $16.5bn out of t

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an indvidual account here: